Trevena, Inc. is a clinical stage biopharmaceutical company. It discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors. The company product pipeline consists of TRV027, TRV130, TRV734, and Delta Opiod. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in King of Prussia, PA.
